Using a patient derived xenograft model of CML, Scott et al. (2016) were able to demonstrate significant targeting of CML stem cells with the EZH2 inhibitor Tazemetostat in combination with TKI compared to TKI treatment alone. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.